Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Qiagen has entered into a collaboration with Max Planck Institute for Infection Biology (MPIIB) to develop a molecular diagnostic test that will evaluate the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.
Subscribe to our email newsletter
The new test will be designed to enable early treatment before reactivation of the TB disease, as a follow up to those who test positive for latent TB.
The company is believed to strengthen its infectious disease portfolio with development of DNA-/RNA-based test that complements QuantiFERON-TB Gold test for latent TB.
The new molecular reflex assay, which is likely to be a PCR-based test targeting multiple biomarkers, will be designed to run on the QIAsymphony modular automation platform.
The test will use whole blood transcription profiling, a new diagnostic technology developed at the Max Planck Institute’s Department of Immunology
The financial terms of the agreement have not been disclosed.